Healthcare provider profile · identity verified

Edwin Solorzano, MD

Family Practice · BELLFLOWER, CA · NPI 1811064751

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	831	542
Metformin Hcl	Metformin Hcl	430	275
Amlodipine Besylate	Amlodipine Besylate	427	279
Lisinopril	Lisinopril	423	293
Losartan Potassium	Losartan Potassium	416	254
Rosuvastatin Calcium	Rosuvastatin Calcium	341	210
Glipizide	Glipizide	287	184
Omeprazole	Omeprazole	287	216
Levothyroxine Sodium	Levothyroxine Sodium	275	167
Pantoprazole Sodium	Pantoprazole Sodium	232	140
Gabapentin	Gabapentin	227	145
Hydrochlorothiazide	Hydrochlorothiazide	200	131
Meloxicam	Meloxicam	193	137
Simvastatin	Simvastatin	189	125
Bisoprolol Fumarate	Bisoprolol Fumarate	184	93
Tamsulosin Hcl	Tamsulosin Hcl	179	115
Alendronate Sodium	Alendronate Sodium	177	125
Finasteride	Finasteride	170	89
Terazosin Hcl	Terazosin Hcl	158	83
Ibuprofen	Ibuprofen	144	108
Atenolol	Atenolol	137	96
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	122	95
Trazodone Hcl	Trazodone Hcl	115	72
Humulin N	Insulin Nph Human Isophane	113	69
Potassium Chloride	Potassium Chloride	112	80
Metoprolol Tartrate	Metoprolol Tartrate	109	70
Azelastine Hcl	Azelastine Hcl	101	61
Furosemide	Furosemide	96	66
Metformin Hcl Er	Metformin Hcl	96	58
Spironolactone	Spironolactone	94	42
Albuterol Sulfate Hfa	Albuterol Sulfate	93	77
Jardiance	Empagliflozin	92	56
Pradaxa	Dabigatran Etexilate Mesylate	92	52
Sertraline Hcl	Sertraline Hcl	84	53
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	82	54
Hydralazine Hcl	Hydralazine Hcl	74	55
Triamcinolone Acetonide	Triamcinolone Acetonide	72	57
Hydrocortisone	Hydrocortisone	64	49
Mirtazapine	Mirtazapine	57	38
Carvedilol	Carvedilol	56	38
Montelukast Sodium	Montelukast Sodium	55	28
Clopidogrel	Clopidogrel Bisulfate	54	35
Lactulose	Lactulose	51	31
Lorazepam	Lorazepam	48	13
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	46	28
Allopurinol	Allopurinol	42	25
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	41	31
Fluoxetine Hcl	Fluoxetine Hcl	39	29
Humulin R	Insulin Regular, Human	39	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	39	12
Pioglitazone Hcl	Pioglitazone Hcl	36	27
Ezetimibe	Ezetimibe	33	21
Isosorbide Mononitrate Er	Isosorbide Mononitrate	33	21
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	33	21
Humulin N Kwikpen	Insulin Nph Human Isophane	31	22
Benazepril Hcl	Benazepril Hcl	29	26
Duloxetine Hcl	Duloxetine Hcl	29	19
Eliquis	Apixaban	29	21
Escitalopram Oxalate	Escitalopram Oxalate	28	17
Cefadroxil	Cefadroxil	27	27
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	26	13
Betamethasone Valerate	Betamethasone Valerate	25	18
Famotidine	Famotidine	25	18
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	25	19
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	24	24
Alprazolam	Alprazolam	23	suppressed
Fenofibrate	Fenofibrate	23	14
Fluticasone Propionate	Fluticasone Propionate	23	17
Nitroglycerin	Nitroglycerin	22	15
Spiriva Respimat	Tiotropium Bromide	22	13
Warfarin Sodium	Warfarin Sodium	22	19
Estradiol	Estradiol	21	19
Ibandronate Sodium	Ibandronate Sodium	21	12
Buspirone Hcl	Buspirone Hcl	20	suppressed
Naproxen	Naproxen	20	19
Chlorthalidone	Chlorthalidone	19	14
Ondansetron Odt	Ondansetron	19	15
Propranolol Hcl	Propranolol Hcl	19	12
Metoprolol Succinate	Metoprolol Succinate	18	16
Pravastatin Sodium	Pravastatin Sodium	18	14
Prednisone	Prednisone	18	17
Tramadol Hcl	Tramadol Hcl	18	suppressed
Clonidine Hcl	Clonidine Hcl	17	11
Digoxin	Digoxin	17	13
Fluocinonide	Fluocinonide	17	suppressed
Liraglutide	Liraglutide	17	13
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	16	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	12
Venlafaxine Hcl Er	Venlafaxine Hcl	16	13
Victoza 2-Pak	Liraglutide	16	13
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	15	15
Colchicine	Colchicine	15	suppressed
Metronidazole	Metronidazole	15	15
Alvesco	Ciclesonide	14	12
Ketoconazole	Ketoconazole	14	12
Latanoprost	Latanoprost	14	suppressed
Ondansetron Hcl	Ondansetron Hcl	14	12
Wixela Inhub	Fluticasone Propion/Salmeterol	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Donepezil Hcl	Donepezil Hcl	13	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Ciclopirox	Ciclopirox	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	12
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Verapamil Hcl	Verapamil Hcl	12	suppressed
Amoxicillin	Amoxicillin	11	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	11
Glipizide-Metformin	Glipizide/Metformin Hcl	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Nystatin	Nystatin	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Trospium Chloride	Trospium Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error